Redeye provides an update following Iconovo’s Q2 report.
Redeye updates its estimates and valuation following Vitec releasing its Q2 2024 report.
Redeye updates its estimates and valuation following Lifco releasing its Q2 2024 report.
Elanders presented a decent Q2 2024 report with flat organic sales y/y, partly supported by easier c...
Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a mixed...
Redeye takes a positive stance towards Fortnox following an overall solid Q2 report, with strong gro...
- Q2 sales SEK 54m, EBIT SEK -1.0m, vs. ABGSCe 52m and -1.
- Q2 showed turnaround in organic growth... - ...and confirmed demand trough - Low valuation and in ...
- Q2: Gross margin lead the way to a 9% adj. EBITA beat vs cons - Positive comments on demand across...
Redeye sees a Q2 report coming in below our expectations on margins and EBITA, as all three Division...
- Adj. EBITA of SEK 161m (0% vs ABGSC, -3% vs cons) - Est's down 2-3% on lower effects of cost savin...
Redeye’s first comments follow this morning’s Q2 report from Tagmaster, which again showed lower org...
Redeye comments on Carasent’s Q2 2024 report, which came in slightly lower on revenues.
Redeye provides its initial take on Vitec’s Q2 2024 report, which mostly exceeded our estimates.
Redeye sees an overall solid report, with the rebound in ACV being the highlight.
Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and ...
- Q2: Adj. EBITDA of NOK 1m vs. our NOK -2m - New targets more achievable with Sainsbury's and Merca...
Q-linea and its distribution partners continue to advance pilot and tender process activities, which...
Redeye provides its initial take on Lifco’s Q2 2024 report, which came in broadly above our estimate...
Redeye comments on Alligators Q2 report and updates its base case.
